First results from CORE-008 cohort A: Phase 2 study of intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naïve non-muscle invasive bladder cancer.
Gary D. Steinberg, Shane M. Pearce, Laurence Belkoff, Brian C. Mazzarella et autres